KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt to Equity: 2012-2025

Historic Debt to Equity for Halozyme Therapeutics (HALO) over the last 12 years, with Sep 2025 value amounting to $3.00.

  • Halozyme Therapeutics' Debt to Equity fell 9.77% to $3.00 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.00, marking a year-over-year decrease of 9.77%. This contributed to the annual value of $4.14 for FY2024, which is 76.86% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Debt to Equity of $3.00 as of Q3 2025, which was down 33.89% from $4.54 recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Debt to Equity ranged from a high of $22.69 in Q1 2023 and a low of $0.32 during Q3 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Debt to Equity value was $5.19 (recorded in 2024), while the average stood at $8.02.
  • As far as peak fluctuations go, Halozyme Therapeutics' Debt to Equity skyrocketed by 6,495.68% in 2023, and later tumbled by 76.86% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Debt to Equity (Quarterly) stood at $4.45 in 2021, then spiked by 99.27% to $8.87 in 2022, then surged by 101.68% to $17.89 in 2023, then tumbled by 76.86% to $4.14 in 2024, then fell by 9.77% to $3.00 in 2025.
  • Its last three reported values are $3.00 in Q3 2025, $4.54 for Q2 2025, and $3.13 during Q1 2025.